Search hospitals > Tennessee > Franklin
Vanderbilt-Ingram Cancer Center Cool Springs
Claim this profileFranklin, Tennessee 37064
Global Leader in Cancer
Global Leader in Breast Cancer
Conducts research for Lung Cancer
Conducts research for Head and Neck Cancers
Conducts research for Leukemia
129 reported clinical trials
11 medical researchers
Summary
Vanderbilt-Ingram Cancer Center Cool Springs is a medical facility located in Franklin, Tennessee. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Head and Neck Cancers, Leukemia and other specialties. Vanderbilt-Ingram Cancer Center Cool Springs is involved with conducting 129 clinical trials across 285 conditions. There are 11 research doctors associated with this hospital, such as Elizabeth J. Davis, Vandana Abramson, M.D., Jordan Berlin, MD, and Ingrid A Mayer, MD.Area of expertise
1Cancer
Global LeaderStage IV
Stage II
Stage III
2Breast Cancer
Global LeaderER positive
HER2 positive
HER2 negative
Top PIs
Elizabeth J. DavisVanderbilt University/Ingram Cancer Center4 years of reported clinical research
Studies Sarcoma
Studies Tumors
16 reported clinical trials
21 drugs studied
Vandana Abramson, M.D.Vanderbilt University/Ingram Cancer Center7 years of reported clinical research
Expert in Breast Cancer
Studies Cancer
13 reported clinical trials
28 drugs studied
Jordan Berlin, MDVanderbilt-Ingram Cancer Center7 years of reported clinical research
Studies Colorectal Cancer
Studies Solid Tumors
13 reported clinical trials
21 drugs studied
Ingrid A Mayer, MDVanderbilt University/Ingram Cancer Center3 years of reported clinical research
Studies Breast Cancer
Studies Cancer
9 reported clinical trials
28 drugs studied
Clinical Trials running at Vanderbilt-Ingram Cancer Center Cool Springs
Breast Cancer
Bladder Carcinoma
Non-Small Cell Lung Cancer
Bladder Cancer
Lung Cancer
Renal Cell Carcinoma
Gallbladder Cancer
Cancer
Meningioma
Penile Cancer
T-DM1 + Tucatinib
for Breast Cancer
This phase III trial studies how well trastuzumab emtansine (T-DM1) and tucatinib work in preventing breast cancer from coming back (relapsing) in patients with high risk, HER2 positive breast cancer. T-DM1 is a monoclonal antibody, called trastuzumab, linked to a chemotherapy drug, called DM1. Trastuzumab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as HER2 receptors, and delivers DM1 to kill them. Tucatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving T-DM1 and tucatinib may work better in preventing breast cancer from relapsing in patients with HER2 positive breast cancer compared to T-DM1 alone.
Recruiting1 award Phase 313 criteria
Chemotherapy Reduction After Surgery
for Breast Cancer
This trial studies how well paclitaxel, trastuzumab, and pertuzumab work in eliminating further chemotherapy after surgery in patients with HER2-positive stage II-IIIa breast cancer who have no cancer remaining at surgery (either in the breast or underarm lymph nodes) after pre-operative chemotherapy and HER2-targeted therapy. Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Trastuzumab and pertuzumab are both a form of "targeted therapy" because they work by attaching themselves to specific molecules (receptors) on the surface of tumor cells, known as HER2 receptors. When these drugs attach to HER2 receptors, the signals that tell the cells to grow are blocked and the tumor cell may be marked for destruction by the body's immune system. Giving paclitaxel, trastuzumab, and pertuzumab may enable fewer chemotherapy drugs to be given without compromising patient outcomes compared to the usual treatment.
Recruiting1 award Phase 227 criteria
Sacituzumab Govitecan
for Brain Metastases from Breast Cancer
This phase II trial studies the effect of sacituzumab govitecan in treating patients with HER2-negative breast cancer that has spread to the brain (brain metastases). Sacituzumab govitecan is a monoclonal antibody, called sacituzumab, linked to a chemotherapy drug, called govitecan. Sacituzumab is a form of targeted therapy because it attaches to specific molecules on the surface of cancer cells, known as Trop-2 receptors, and delivers govitecan to kill them. Giving sacituzumab govitecan may shrink the cancer in the brain and/or extend the time until the cancer gets worse.
Recruiting1 award Phase 212 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Vanderbilt-Ingram Cancer Center Cool Springs?
Vanderbilt-Ingram Cancer Center Cool Springs is a medical facility located in Franklin, Tennessee. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Head and Neck Cancers, Leukemia and other specialties. Vanderbilt-Ingram Cancer Center Cool Springs is involved with conducting 129 clinical trials across 285 conditions. There are 11 research doctors associated with this hospital, such as Elizabeth J. Davis, Vandana Abramson, M.D., Jordan Berlin, MD, and Ingrid A Mayer, MD.